Skip to product information
1 of 3

ColoAlert | Cancer Screening

ColoAlert | Cancer Screening

Regular price €199.00 EUR
Regular price Sale price €199.00 EUR
Sale Sold out
This product is available only for Italy, United Arab Emirates and Ireland


ColoAlert is a CE-IVD marked, non-invasive and specific colorectal cancer screening test.  


  • Sensitivity of 85%, even in the early stages of tumor development 1
  • Effective even in the absence of blood loss in the stool
  • Non-invasive, painless and fast (takes less than 5 minutes)
  • 60% more cases detected than occult blood testing (FIT) 1, 2

This test can check for possible colorectal cancer at any stage of development, with a completely painless sample collection method.

Early diagnosis plays a crucial role in the success of therapies, but obtaining it is not easy as the symptoms of the tumor are silent in the early stages of development.

Make your prevention plan efficient, sustainable and timely with ColoAlert


    1) Dollinger MM et al. (2018), ClinLab 64(10), 1719-1730.

    2) Gies et al. (2018). Gastroenterology 154(1), 93-104. 3) Cooper GS et al. (2018). Dig Dis Sci. 63(6), 1449-1453.

    Cutting-edge Technology

    Through a DNA analysis this test is able to verify the presence of the tumor in all its stages, starting from the stool sample only and with a specificity of 92%.

    Privacy and Security

    Compliant with European regulations on security and privacy (GDPR) and CE-IVD mark.

    Free shipping

    Free shipping costs both to receive the collection kit and to send the sample to the laboratory.

    Painless SampleCollection

    To perform the test, you need to collect a stool sample. The process is simple, non-invasive and takes no more than 5 minutes.

    See more about the product

    Next Generation Screening

    • 3 years of coverage

    • 85% Sensitivity *

    • 92% Specificity **

    • Painless and Non Invasive

    • Early Detection

    • +60% efficiency compared to FIT

    1 of 6

    * Sensitivity, ability to correctly identify cases of patients actually suffering from the disease
    ** Specificity, ability to correctly identify cases of patients not affected by the disease

    • Buy and receive the test wherever you want

      Free shipping and sending the sample to the lab

    • Register the test on the Genome Manager portal

      Keep your data in order and secure in your personal account

    • Get digital results a few days after arriving at the lab

      Receive the digital panels signed and commented by the doctor

    The real danger of colorectal cancer

    About 70% of colon cancer cases affect people over the age of 50.
    For those over 50 and for those with a family history of colorectal cancer, it is therefore strongly recommended to follow a constant screening plan and not wait for symptoms to appear.
    Signs such as blood loss in the stool are found mainly in the third and fourth stages of tumor development - the penultimate and last, respectively. In these phases the tumor mass is so extensive that it is damaged by the passage of stools along the intestine, for this reason it is damaged and releases traces of blood.
    Waiting for obvious symptoms to appear has a strong impact not only on the cost of therapies, but also on their chances of success, which are much lower in the last two stages of tumor development than in cases of timely diagnosis.

    1 of 4

    ColoAlert and FIT

    The fecal immunochemical test (FIT) detects the presence of polyps in the intestinal tract that have grown to a cancerous state. These polyps reach such a voluminous mass that they are damaged when the stool passes through the intestine, releasing traces of blood.
    The presence of traces of blood in the stool due to a polyp, therefore, depends on an advanced degree of development of the tumor mass. Furthermore, we must not forget that other problems, unrelated to the presence of a tumor, can also lead to blood loss of this type. Let's think, for example, of intestinal ulcers, hemorrhoids, diverticulosis and more.

    To overcome all these constraints, ColoAlert has been designed with a double analysis:

    • Fecal Occult Blood Test GOLD

      Next Generation version GOLD

      to detect the presence of hemoglobin, and consequently blood, in the stools.

    • DNA Test

      Real Time PCR technology

      Genetic analysis to detect tumor markers and the quantification of human DNA.

    The identification of multiple risk factors allows ColoAlert to overcome the limits connected not only to blood traces dispersed in the stools, but also to all those symptoms that can be confused with other non-pathological problems or problems that cannot be found in the early stages of tumor development.

    ColoAlert and Colonoscopy

    The diagnostic test for identifying colorectal cancer is colonoscopy.
    This exam allows you to receive a real-time picture of the clinical state of the colorectum. Despite the various advantages conferred by this examination, many patients are reluctant to undergo it and it is not chosen for a constant prevention strategy.
    The main frictions are related to the preoperative diet and the degree of invasiveness and pain of the type of exam. Many gastroenterologists declare that a percentage of patients avoid undergoing colonoscopy even if prescribed by the doctor and already booked.
    In these cases ColoAlert helps to create a sustainable, non-invasive and painless screening strategy, which patients can follow even in the long term without particular efforts.
    It also allows, with a sensitivity of 85% and a specificity of 92%, to achieve an efficacy such as to recommend colonoscopy in cases where it is really required, as well as giving a strong motivation to those patients who are undecided about colonoscopy.

    Genetic Analysis reveals:

    • Human DNA (hDNA)

      The above-threshold amount of human DNA in stools indicates an intensive proliferation of cells. This factor can be associated with a strong inflammation or to the development of polyps / tumoral mass.

    • Biomarker KRAS

      KRAS gene mutations are present in approximately 25% of cancers, particularly 40% of colorectal cancer cases.

      This makes these genetic mutations one of the most linked to cancer.

    • Biomarker BRAF

      BRAF gene mutations are present in about 10% of colorectal cancer. In these cases it is possible that the tumor is of a rare type, resistant to traditional therapies, which makes timely detection even more important.

    The uniqueness of the Coloalert test

    Early detection

    The ColoAlert test identifies potential cancer even without obvious symptoms or the presence of occult blood in the stool. It is therefore effective in all stages of the development of the disease.

    100% Painless

    Practical and simple, with two devices: a swab and a vial to collect the two stool samples in a quick and totally non-invasive way.

    92% Specificity

    This metric studies the accuracy of the negative cases identified by the test. The negative result of the ColoAlert test is really reliable.

    3 years of coverage

    The speed with which a possible tumor mass develops changes based on several factors, such as age, but the negative result of the ColoAlert test allows you to wait up to 3 years before repeating the screening process.